|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GRIPAP1 |
Gene summary for GRIPAP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GRIPAP1 | Gene ID | 56850 |
| Gene name | GRIP1 associated protein 1 | |
| Gene Alias | GRASP-1 | |
| Cytomap | Xp11.23 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q4V328 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56850 | GRIPAP1 | LZE4T | Human | Esophagus | ESCC | 1.06e-09 | 2.30e-01 | 0.0811 |
| 56850 | GRIPAP1 | LZE7T | Human | Esophagus | ESCC | 3.69e-07 | 3.34e-01 | 0.0667 |
| 56850 | GRIPAP1 | LZE8T | Human | Esophagus | ESCC | 1.51e-07 | 2.15e-01 | 0.067 |
| 56850 | GRIPAP1 | LZE20T | Human | Esophagus | ESCC | 2.76e-03 | 1.26e-01 | 0.0662 |
| 56850 | GRIPAP1 | LZE24T | Human | Esophagus | ESCC | 1.33e-08 | 2.67e-01 | 0.0596 |
| 56850 | GRIPAP1 | P1T-E | Human | Esophagus | ESCC | 1.08e-08 | 3.98e-01 | 0.0875 |
| 56850 | GRIPAP1 | P2T-E | Human | Esophagus | ESCC | 5.75e-15 | 4.08e-01 | 0.1177 |
| 56850 | GRIPAP1 | P4T-E | Human | Esophagus | ESCC | 1.23e-16 | 3.37e-01 | 0.1323 |
| 56850 | GRIPAP1 | P5T-E | Human | Esophagus | ESCC | 1.35e-19 | 1.25e-01 | 0.1327 |
| 56850 | GRIPAP1 | P8T-E | Human | Esophagus | ESCC | 2.55e-26 | 3.27e-01 | 0.0889 |
| 56850 | GRIPAP1 | P9T-E | Human | Esophagus | ESCC | 6.51e-06 | 2.22e-01 | 0.1131 |
| 56850 | GRIPAP1 | P10T-E | Human | Esophagus | ESCC | 4.27e-19 | 1.92e-01 | 0.116 |
| 56850 | GRIPAP1 | P11T-E | Human | Esophagus | ESCC | 5.96e-17 | 6.35e-01 | 0.1426 |
| 56850 | GRIPAP1 | P12T-E | Human | Esophagus | ESCC | 2.26e-17 | 1.90e-01 | 0.1122 |
| 56850 | GRIPAP1 | P15T-E | Human | Esophagus | ESCC | 4.87e-13 | 2.91e-01 | 0.1149 |
| 56850 | GRIPAP1 | P16T-E | Human | Esophagus | ESCC | 2.99e-14 | 2.76e-01 | 0.1153 |
| 56850 | GRIPAP1 | P17T-E | Human | Esophagus | ESCC | 6.49e-04 | 2.04e-01 | 0.1278 |
| 56850 | GRIPAP1 | P20T-E | Human | Esophagus | ESCC | 1.31e-12 | 2.47e-01 | 0.1124 |
| 56850 | GRIPAP1 | P21T-E | Human | Esophagus | ESCC | 5.15e-16 | 1.74e-01 | 0.1617 |
| 56850 | GRIPAP1 | P22T-E | Human | Esophagus | ESCC | 4.76e-26 | 4.90e-01 | 0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003238618 | Esophagus | ESCC | regulation of intracellular transport | 243/8552 | 337/18723 | 3.20e-23 | 7.25e-21 | 243 |
| GO:0033157110 | Esophagus | ESCC | regulation of intracellular protein transport | 169/8552 | 229/18723 | 3.31e-18 | 3.23e-16 | 169 |
| GO:001619715 | Esophagus | ESCC | endosomal transport | 168/8552 | 230/18723 | 2.28e-17 | 1.93e-15 | 168 |
| GO:0090150110 | Esophagus | ESCC | establishment of protein localization to membrane | 182/8552 | 260/18723 | 1.27e-15 | 8.19e-14 | 182 |
| GO:0072659110 | Esophagus | ESCC | protein localization to plasma membrane | 193/8552 | 284/18723 | 1.95e-14 | 1.03e-12 | 193 |
| GO:199077819 | Esophagus | ESCC | protein localization to cell periphery | 217/8552 | 333/18723 | 4.08e-13 | 1.88e-11 | 217 |
| GO:009887615 | Esophagus | ESCC | vesicle-mediated transport to the plasma membrane | 99/8552 | 136/18723 | 1.13e-10 | 3.39e-09 | 99 |
| GO:190547519 | Esophagus | ESCC | regulation of protein localization to membrane | 117/8552 | 175/18723 | 1.14e-08 | 2.26e-07 | 117 |
| GO:003150314 | Esophagus | ESCC | protein-containing complex localization | 139/8552 | 220/18723 | 1.14e-07 | 1.85e-06 | 139 |
| GO:190437519 | Esophagus | ESCC | regulation of protein localization to cell periphery | 85/8552 | 125/18723 | 3.63e-07 | 5.06e-06 | 85 |
| GO:1903076110 | Esophagus | ESCC | regulation of protein localization to plasma membrane | 72/8552 | 104/18723 | 9.74e-07 | 1.23e-05 | 72 |
| GO:006195114 | Esophagus | ESCC | establishment of protein localization to plasma membrane | 44/8552 | 60/18723 | 1.25e-05 | 1.15e-04 | 44 |
| GO:00324565 | Esophagus | ESCC | endocytic recycling | 51/8552 | 73/18723 | 2.47e-05 | 2.10e-04 | 51 |
| GO:00995324 | Esophagus | ESCC | synaptic vesicle endosomal processing | 9/8552 | 10/18723 | 5.09e-03 | 1.92e-02 | 9 |
| GO:00995635 | Esophagus | ESCC | modification of synaptic structure | 16/8552 | 22/18723 | 9.46e-03 | 3.28e-02 | 16 |
| GO:003238621 | Liver | HCC | regulation of intracellular transport | 231/7958 | 337/18723 | 1.99e-22 | 3.40e-20 | 231 |
| GO:003315721 | Liver | HCC | regulation of intracellular protein transport | 165/7958 | 229/18723 | 8.37e-20 | 1.15e-17 | 165 |
| GO:001619721 | Liver | HCC | endosomal transport | 154/7958 | 230/18723 | 4.74e-14 | 2.95e-12 | 154 |
| GO:009015012 | Liver | HCC | establishment of protein localization to membrane | 168/7958 | 260/18723 | 4.07e-13 | 2.13e-11 | 168 |
| GO:007265921 | Liver | HCC | protein localization to plasma membrane | 177/7958 | 284/18723 | 1.02e-11 | 4.18e-10 | 177 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GRIPAP1 | SNV | Missense_Mutation | novel | c.1667C>T | p.Ala556Val | p.A556V | Q4V328 | protein_coding | tolerated(0.18) | probably_damaging(0.994) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GRIPAP1 | SNV | Missense_Mutation | c.1888N>A | p.Glu630Lys | p.E630K | Q4V328 | protein_coding | deleterious(0.02) | benign(0.093) | TCGA-AN-A0XO-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| GRIPAP1 | SNV | Missense_Mutation | c.571N>A | p.Glu191Lys | p.E191K | Q4V328 | protein_coding | tolerated(0.12) | probably_damaging(0.992) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
| GRIPAP1 | SNV | Missense_Mutation | novel | c.2470N>T | p.Ser824Cys | p.S824C | Q4V328 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GRIPAP1 | SNV | Missense_Mutation | c.1067N>C | p.Leu356Pro | p.L356P | Q4V328 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GRIPAP1 | SNV | Missense_Mutation | c.1314N>A | p.Met438Ile | p.M438I | Q4V328 | protein_coding | tolerated(1) | possibly_damaging(0.871) | TCGA-D8-A1XB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GRIPAP1 | SNV | Missense_Mutation | c.1105G>A | p.Glu369Lys | p.E369K | Q4V328 | protein_coding | tolerated(0.09) | possibly_damaging(0.878) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| GRIPAP1 | SNV | Missense_Mutation | rs782656835 | c.1364G>A | p.Arg455His | p.R455H | Q4V328 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-EW-A1PC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| GRIPAP1 | SNV | Missense_Mutation | novel | c.913N>A | p.Glu305Lys | p.E305K | Q4V328 | protein_coding | tolerated(0.08) | possibly_damaging(0.885) | TCGA-LD-A7W5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
| GRIPAP1 | SNV | Missense_Mutation | novel | c.125N>T | p.Arg42Leu | p.R42L | Q4V328 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-LL-A5YO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |